Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Oncotarget
|
November 20, 2019
Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study
Sarina A Piha-Paul, Matthew H Taylor, Daniel Spitz, et al.
Cell Cycle (Georgetown, Tex.)
|
May 6, 2011
MicroRNA signatures differentiate melanoma subtypes
Elcie Chan, Rajeshvari Patel, Sunitha Nallur, et al.
Journal of Translational Medicine
|
August 30, 2012
Integrated next-generation sequencing of 16S rDNA and metaproteomics differentiate the healthy urine microbiome from asymptomatic bacteriuria in neuropathic bladder associated with spinal cord injury
Derrick E Fouts, Rembert Pieper, Sebastian Szpakowski, et al.
BMJ Open
|
August 29, 2024
Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicentre study
Chia-Chi Lin, Giuseppe Curigliano, Armando Santoro, et al.
Cancer Research Communications
|
June 9, 2025
Defining Non-small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data
Lang Ho Lee, Xin Xu, Thanos Mourikis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 17, 2017
Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer
Enriqueta Felip, Fabrice Barlesi, Benjamin Besse, et al.
Molecular Cancer Therapeutics
|
February 8, 2020
Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071
Sophie Piperno-Neumann, James Larkin, Richard D Carvajal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 5, 2020
PD-1 Blockade in Anaplastic Thyroid Carcinoma
Jaume Capdevila, Lori J Wirth, Thomas Ernst, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 26, 2021
Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
Caroline Even, Hung-Ming Wang, Shau-Hsuan Li, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Oncotarget
|
November 20, 2019
Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study
Sarina A Piha-Paul, Matthew H Taylor, Daniel Spitz, et al.
Cell Cycle (Georgetown, Tex.)
|
May 6, 2011
MicroRNA signatures differentiate melanoma subtypes
Elcie Chan, Rajeshvari Patel, Sunitha Nallur, et al.
Journal of Translational Medicine
|
August 30, 2012
Integrated next-generation sequencing of 16S rDNA and metaproteomics differentiate the healthy urine microbiome from asymptomatic bacteriuria in neuropathic bladder associated with spinal cord injury
Derrick E Fouts, Rembert Pieper, Sebastian Szpakowski, et al.
BMJ Open
|
August 29, 2024
Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicentre study
Chia-Chi Lin, Giuseppe Curigliano, Armando Santoro, et al.
Cancer Research Communications
|
June 9, 2025
Defining Non-small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data
Lang Ho Lee, Xin Xu, Thanos Mourikis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 17, 2017
Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer
Enriqueta Felip, Fabrice Barlesi, Benjamin Besse, et al.
Molecular Cancer Therapeutics
|
February 8, 2020
Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071
Sophie Piperno-Neumann, James Larkin, Richard D Carvajal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 5, 2020
PD-1 Blockade in Anaplastic Thyroid Carcinoma
Jaume Capdevila, Lori J Wirth, Thomas Ernst, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 26, 2021
Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
Caroline Even, Hung-Ming Wang, Shau-Hsuan Li, et al.
Page
of 2